Pricing Log in Create free account
Friday 6 November 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.

Revenue
−0.24%
EPS
+2.48%
Free cash flow
+17.4%
Total debt
+37.5%

Quarter to June 2026, against a year earlier

81.72 7.48 −8.39%
Market cap
$33.9B
P/E
13.4×
Fwd P/E
14.2×
Dividend yield
2.59%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Zoetis Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 2:32 PM ET · Document on sec.gov · Filing index

Red flags

  • Covenant breach

    Zoetis Inc.’s 10-Q reports a breach of a debt covenant, or a waiver to avoid one

    The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale lease-back transactions.

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 7, 2026: 42 added · 15 removed · 43 modified; 13 with only figures updated; 2 moved without change

  1. Modified · Overview of our business

    A summary of our 2026 performance compared with the comparable 2025 periodperiods follows: